Zhonghai Ren

机构：Nanyang Institute of Technology

发表论文 11 篇 · 总被引 108 次 · h-index 3

代表论文

• Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial (2022 · ˜The œLancet. Gastroenterology & hepatology · 被引 88)
• Comparison of Helicobacter pylori positive and negative gastric cancer via multi-omics analysis (2023 · mBio · 被引 13)
• The clinical observation of combined chemotherapy of irinotecan and cisplatin in the treatment of relapsed advanced small cell lung cancer (2008 · The Chinese-German Journal of Clinical Oncology · 被引 3)
• Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study. (2021 · Journal of Clinical Oncology · 被引 2)
• Nutritional status and interventions of nasopharyngeal carcinoma patients treated with radiotherapy (2013 · Zhonghua zhongliu fangzhi zazhi · 被引 1)
• A preliminary study on K-ras, EGFR, and B-raf mutations of esophageal squamous cell carcinoma (2011 · The Chinese-German Journal of Clinical Oncology · 被引 1)